TR200001059T2 - Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi. - Google Patents

Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi.

Info

Publication number
TR200001059T2
TR200001059T2 TR2000/01059T TR200001059T TR200001059T2 TR 200001059 T2 TR200001059 T2 TR 200001059T2 TR 2000/01059 T TR2000/01059 T TR 2000/01059T TR 200001059 T TR200001059 T TR 200001059T TR 200001059 T2 TR200001059 T2 TR 200001059T2
Authority
TR
Turkey
Prior art keywords
hypercoagulation
treatment
acquired
deficiency
sepsis
Prior art date
Application number
TR2000/01059T
Other languages
English (en)
Inventor
William Grinnell Brian
Lawrence Hartman Daniel
Betty Yan Sau-Chi
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200001059T2 publication Critical patent/TR200001059T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sepsis, purpura fulminans, meningokokal sepsis, kemik iligi ve diger transplantasyonlar, ciddi yaniklar, gebelik, büyük ameliyatlar, ciddi travmalar ya da ARDS ile ortaya çikan kazanilmis C proteini eksikligi ya da kazanilmis hiper pihtilasma halinden musdarip insan hastalarin tedavisi olup, bu tedavi, kanama komplikasyonlarina neden olmak için düsük bir potansiyeli olan yüksek ölçüde seçici bir terapötik maddenin temin edilmesiyle aktive C proteininin kullanimini içermektedir.
TR2000/01059T 1997-10-20 1998-10-14 Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi. TR200001059T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07

Publications (1)

Publication Number Publication Date
TR200001059T2 true TR200001059T2 (tr) 2000-10-23

Family

ID=26742406

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01059T TR200001059T2 (tr) 1997-10-20 1998-10-14 Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi.

Country Status (27)

Country Link
US (7) US6037322A (tr)
EP (2) EP0913156B1 (tr)
JP (2) JP3805981B2 (tr)
KR (1) KR100798174B1 (tr)
CN (1) CN1276726A (tr)
AT (1) ATE292979T1 (tr)
AU (1) AU748417B2 (tr)
BR (1) BR9812965A (tr)
CA (1) CA2306983A1 (tr)
DE (1) DE69829721T2 (tr)
DK (1) DK0913156T3 (tr)
EA (1) EA002496B1 (tr)
ES (1) ES2239382T3 (tr)
HU (2) HUP0001237A3 (tr)
ID (1) ID24901A (tr)
IL (2) IL135712A0 (tr)
MY (1) MY117655A (tr)
NO (1) NO20002005L (tr)
NZ (1) NZ504026A (tr)
PL (1) PL200515B1 (tr)
PT (1) PT913156E (tr)
SI (1) SI0913156T1 (tr)
TR (1) TR200001059T2 (tr)
TW (1) TWI225404B (tr)
UA (1) UA72194C2 (tr)
WO (1) WO1999020293A1 (tr)
ZA (1) ZA989385B (tr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
BR9809292A (pt) 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
AU1477000A (en) * 1998-11-13 2000-06-05 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
ATE232739T1 (de) * 1998-11-23 2003-03-15 Lilly Co Eli Protein c zur behandlung von sichelzellanämie und thalassämie
CA2398929C (en) * 2000-02-04 2011-05-31 The Scripps Research Institute Neuroprotective, antithrombotic and anti-flammatory uses of activated protein c (apc)
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6736972B1 (en) 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2001245319A1 (en) * 2000-03-28 2001-10-08 Eli Lilly And Company Methods of treating diseases with activated protein c
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
CA2410567A1 (en) * 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
WO2002069232A2 (en) 2001-02-19 2002-09-06 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
ATE550073T1 (de) * 2001-06-13 2012-04-15 Univ Sydney Protein c für die wundheilung
AU2002354951A1 (en) * 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
CA2463655A1 (en) 2001-10-15 2003-04-24 Chiron Corporation Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
JP2005535394A (ja) * 2002-08-13 2005-11-24 アルビオス テクノロジーズ インコーポレーティッド 選択的血漿交換方法
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
JPWO2004065418A1 (ja) * 2003-01-20 2006-06-29 中外製薬株式会社 抗ｐｃｉ中和抗体
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
CN1787741B (zh) 2003-05-15 2011-08-17 唐纳士公司 用于预防和治疗败血症的方法与组合物
US7498305B2 (en) * 2003-07-08 2009-03-03 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20090227669A1 (en) * 2004-01-23 2009-09-10 The University Of Toledo Compositions and Methods for Perioperative Bladder Instillation
BRPI0508992A (pt) * 2004-03-17 2007-09-04 Chiron Corp tratamento de pneumonia severa pela administração de tfpi
EP1745145A4 (en) * 2004-05-11 2008-03-26 Heptest Lab Inc COMPOSITIONS, KIT AND METHOD IN ONE STEP FOR MONITORING COMPOUNDS HAVING XA AND / OR ANTIFACTOR IIA ANTIFACTOR ACTIVITIES
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
WO2006124770A2 (en) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Treatment of sepsis and inflammation with alpha2a adrenergic antagonists
US20100297099A1 (en) * 2005-06-24 2010-11-25 Lars Otto Uttenthal Airway Administration of Activated Protein C in Inflammatory Conditions Affecting the Respiratory Tract
SG163567A1 (en) 2005-07-05 2010-08-30 Biotempt Bv Treatment of tumors
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
CA2668187A1 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
RU2490722C1 (ru) * 2012-04-24 2013-08-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ восстановления кровотока в регионе тромбированной вены в эксперименте
IN2014DN11181A (tr) 2012-07-04 2015-10-02 Univ Sydney
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry
US20170035862A1 (en) 2014-04-16 2017-02-09 Zz Biotech Llc Use of APC analogue for wound healing
CN112292467A (zh) 2018-06-15 2021-01-29 山特维克材料技术公司 双相不锈钢带及其制造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3434326B2 (ja) * 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 成人呼吸窮迫症候群（ａｒｄｓ）予防、治療剤
JP2825739B2 (ja) * 1993-09-20 1998-11-18 帝人株式会社 急性肝不全治療剤
JP3802104B2 (ja) * 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
WO1997020043A1 (en) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
BR9809292A (pt) * 1997-04-28 2000-07-04 Lilly Co Eli Métodos aperfeiçoados para o processamento de proteìna c ativada
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
JP2005097313A (ja) 2005-04-14
KR100798174B1 (ko) 2008-01-24
AU9804098A (en) 1999-05-10
US20010036456A1 (en) 2001-11-01
US6268337B1 (en) 2001-07-31
NO20002005D0 (no) 2000-04-17
HK1020529A1 (en) 2000-05-12
EA002496B1 (ru) 2002-06-27
ATE292979T1 (de) 2005-04-15
IL135712A (en) 2010-12-30
EP0913156B1 (en) 2005-04-13
AU748417B2 (en) 2002-06-06
DE69829721D1 (de) 2005-05-19
JP2001520199A (ja) 2001-10-30
PL340096A1 (en) 2001-01-15
HUP0100025A2 (hu) 2001-05-28
US6268344B1 (en) 2001-07-31
US6489296B1 (en) 2002-12-03
UA72194C2 (en) 2005-02-15
EP1449537A3 (en) 2005-09-21
ES2239382T3 (es) 2005-09-16
PL200515B1 (pl) 2009-01-30
MY117655A (en) 2004-07-31
DE69829721T2 (de) 2006-02-09
CN1276726A (zh) 2000-12-13
TWI225404B (en) 2004-12-21
US6156734A (en) 2000-12-05
US6008199A (en) 1999-12-28
CA2306983A1 (en) 1999-04-29
BR9812965A (pt) 2001-03-20
WO1999020293A1 (en) 1999-04-29
EP0913156A1 (en) 1999-05-06
HUP0001237A3 (en) 2002-01-28
DK0913156T3 (da) 2005-06-27
NZ504026A (en) 2002-12-20
EP1449537A2 (en) 2004-08-25
HU224901B1 (en) 2006-04-28
HUP0001237A2 (hu) 2000-08-28
JP3805981B2 (ja) 2006-08-09
KR20010031217A (ko) 2001-04-16
PT913156E (pt) 2005-08-31
SI0913156T1 (en) 2005-10-31
NO20002005L (no) 2000-05-16
ZA989385B (en) 2000-04-14
EA200000445A1 (ru) 2000-10-30
US6426071B2 (en) 2002-07-30
HUP0100025A3 (en) 2003-08-28
ID24901A (id) 2000-08-31
IL135712A0 (en) 2001-05-20
US6037322A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
TR200001059T2 (tr) Kazanılmış protein C eksikliği veya hiper pıhtılaşma durumlarının tedavisi.
TR199802421T2 (tr) Doku yenilenmesini düzenleyen maddeler.
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
TR199802423T2 (tr) Konsantre antikor terkibi.
TR200100882T2 (tr) Hidrokoloid şekerleme
EP2112161A3 (en) Peptides that lower blood glucose levels
NO921454L (no) Fremgangsmaater og blandinger for heling av ben
IS4523A (is) Speglunarskuggaefni, sem helst lengi í blóði, tilsjúkdómsgreininga
DE69922822D1 (de) Rekombinante haarbehandlungsmittel
TR200102784T2 (tr) Diyabet tedavisi için ilaç
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
NZ332954A (en) Use of BPI protein products to treat humans with hemorrhage due to trauma
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
ATE264340T1 (de) Stabilisierung von gefriergetrocknetem kuchen
FR2759701B1 (fr) Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
DE60007973D1 (de) Matrixprotein zusammensetzungen für pfropfung in nicht mineralisierten geweben
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
TR199802270A2 (tr) Sülfonamid-ikame etmis anelize 5-halka-bilesikleri.
TR199800168A2 (tr) Insan endoglin geni yükselticisi ve kullanimi.
TR199801976T2 (tr) Mukozanin viskozitesini en iyi duruma getirmek ve bagirsak fonksiyonlarini uyarmak için ilaç.
IS5231A (is) Vefjaþáttur sem hefur áhrif á blóðæðarmyndun
EP1645270A3 (en) Control of pain with endogenous cannabinoids
NZ511034A (en) Methods of downmodulating the immune response to therapeutic proteins
NO984965L (no) Komponent B som cicatrisant